Pluri Biotech
- Biotech or pharma, therapeutic R&D
Pluri is a leading developer of allogeneic placenta-derived cell therapies, including immunotherapy & late-stage adherent cell assets. Its proprietary manufacturing platform allows for a robust, efficient, scalable process to produce cell-based products.
Pluri is offering two in-licensing opportunities, A. licensing the Allogeneic MAIT (unconventional T) Platform for CAR and TCR therapeutics, and/or B. licensing of a CAR-MAIT product for solid tumors.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}